A

Acticor Biotech SA
PAR:ALACT

Watchlist Manager
Acticor Biotech SA
PAR:ALACT
Watchlist
Price: 0.25 EUR Market Closed
Market Cap: 3.9m EUR

Acticor Biotech SA
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Acticor Biotech SA
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
A
Acticor Biotech SA
PAR:ALACT
EPS (Diluted)
-€1
CAGR 3-Years
-28%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
EPS (Diluted)
€0
CAGR 3-Years
29%
CAGR 5-Years
-14%
CAGR 10-Years
-12%
Nanobiotix SA
PAR:NANO
EPS (Diluted)
-€1
CAGR 3-Years
4%
CAGR 5-Years
12%
CAGR 10-Years
0%
Inventiva SA
PAR:IVA
EPS (Diluted)
-€2
CAGR 3-Years
-28%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
EPS (Diluted)
$0
CAGR 3-Years
42%
CAGR 5-Years
16%
CAGR 10-Years
1%
DBV Technologies SA
PAR:DBV
EPS (Diluted)
-$1
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
3%
No Stocks Found

Acticor Biotech SA
Glance View

Market Cap
3.9m EUR
Industry
Biotechnology

Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.

ALACT Intrinsic Value
Not Available

See Also

What is Acticor Biotech SA's EPS (Diluted)?
EPS (Diluted)
-1.5 EUR

Based on the financial report for Dec 31, 2023, Acticor Biotech SA's EPS (Diluted) amounts to -1.5 EUR.

What is Acticor Biotech SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
3%

Over the last year, the EPS (Diluted) growth was -2%. The average annual EPS (Diluted) growth rates for Acticor Biotech SA have been -28% over the past three years , 3% over the past five years .

Back to Top